Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
POINT Biopharma Global Inc. (PNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC.",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"Schedule A",
"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies"
08/14/2023 8-K Quarterly results
Docs: "POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Enrollment in PNT2002's SPLASH trial is complete and top line data is expected in the fourth quarter of 2023"
08/03/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
02/07/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
09/14/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "13,900,000 Shares1 POINT Biopharma Global Inc.",
"POINT Biopharma Global Inc. 4850 West 78th Street",
"POINT Biopharma Prices Public Offering of Common Stock"
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Announces Proposed Public Offering of Common Stock"
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022",
"PNT2002 1 3.7 0 0.0"
09/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial"
06/03/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/25/2022 8-K Quarterly results
Docs: "POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial"
02/25/2022 8-K Quarterly results
02/15/2022 8-K Other Events  Interactive Data
12/10/2021 8-K Quarterly results
12/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes Justyna Kelly"
11/19/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/28/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
06/21/2021 8-K Other Events
06/09/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT. Special Meeting Scheduled for June 29, 2021"
06/04/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
04/28/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
08/06/2020 8-K Quarterly results
07/16/2020 8-K Quarterly results
07/10/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy